Sadia Z Shah

Dr. Sadia Z Shah

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Clinical Infection in Practice
Verified
Journal Article
Open access
FSF. Stancampiano
F. Stancampiano
NJN. Jhawar
N. Jhawar
WAW. Alsafi
W. Alsafi
JVJ. Valery
J. Valery
DHD.M. Harris
D.M. Harris
CLC.R. Libertin
C.R. Libertin
Remdesivir, an antiviral drug routinely used in the treatment of COVID-19 has not yet received FDA approval for use in patients with advanced kidney disease defined as GFR < 30 mL/min/1.73 m2. There is concern that an excipient in Veklury (Gilead’s proprietary name for remdesivir) called sulfobutylether-beta-cyclodextrin (SBECD), which is renally cleared, may accumulate and reach toxic levels in patients with advanced kidney disease. The aim of this study was to summarize characteristics and incidence of adverse events of chronic kidney disease (CKD) patients who received remdesivir during hospitalization. Design, setting, participants, and measurements. We retrospectively studied patients admitted to one of several hospitals of the Mayo Clinic Foundation with the diagnosis of COVID-19 pneumonia and CKD. Laboratory values were also measured when remdesivir was first administered and stopped. All analyses were performed in the overall patient group and three separate subgroups of patients with a GFR ≥ 15, a GFR < 15 and dialysis, and a GFR < 15 and no dialysis. A total of 444 CKD patients who were admitted to the hospital with COVID-19 pneumonia between May 2020 and September 2021 were included. Information was collected on patient characteristics, hospitalization, and adverse events. In the overall cohort, median age was 72 years (Range: 21–100 years), 55.2 % of patients were male, and most (86.5 %) were Caucasian. CKD stage was 3 for 114 patients (25.7 %), 4 for 229 patients (51.6 %), and 5 for 101 patients (22.7 %). A total of 146 patients (32.9 %) were admitted to the ICU, 103 (23.2 %) died in the hospital, and 120 (27.0 %) were on dialysis. The proportion of patients with an adverse event did not differ dramatically between the GFR ≥ 15 (20.9 %), GFR < 15 and dialysis (30.2 %), and GFR < 15 and no dialysis (32.3 %) groups (P = 0.12). Our results suggest that the use of remdesivir in patients with very severe CKD is safe, even in those who are not on renal replacement therapy.

28 July 2023 in Mayo Clinic Proceedings: Digital Health
Verified
Journal Article
Open access
SIShahin Isha
Shahin Isha
SSSadia Z Shah
Sadia Z Shah

13 June 2025 in Clinical and Translational Gastroenterology
Verified
Journal Article
Open access
AAAli Alghubari
Ali Alghubari
COCaroline Olson
Caroline Olson
JBJessica Bradley
Jessica Bradley
RCRamsah Cheah
Ramsah Cheah
SSSadia Z Shah
Sadia Z Shah
LHLesley A. Houghton
Lesley A. Houghton
INTRODUCTION: Gastroesophageal reflux is common in respiratory disease, but the interplay between gastrointestinal mechanisms that expose individuals to reflux and potentially aspiration, and lung mechanics and function remain incompletely understood. Our aim was to investigate this in patients with chronic obstructive pulmonary disease (COPD) and non-idiopathic pulmonary fibrosis (IPF) interstitial lung disease (non-IPF ILD), and compare with our published findings in IPF. METHODS: Fifty-seven patients with COPD (aged: 34–75 years) and 64 with non-IPF ILD (22–75 years) who underwent high-resolution impedance manometry and 24-hour pH impedance together with pulmonary function assessment were compared with 35 IPF patients (51–84 years). RESULTS: COPD patients were less likely to exhibit ineffective esophageal motility (IEM) and/or absent contractility (P = 0.009; P = 0.028), and tended to exhibit esophagogastric junction outflow obstruction (EGJOO) and/or hypercontractility (P = 0.09, P = 0.14) than IPF and non-IPF ILD patients. Notably, integrated relaxation pressure correlated with esophageal length index (ELI) (P = 0.048) and inspiratory LESP (P = 0.003), with latter 2 correlating with each other (P < 0.001). EGJOO patients tended to have fewer proximal reflux events and reduced pulmonary function, with the latter inversely correlating with ELI (P < 0.05). Non-IPF ILD patients were less likely to exhibit EGJOO than COPD patients (P = 0.27), and less likely to exhibit IEM (P = 0.07) than IPF patients. However, those with IEM or EGJOO exhibited greater proportions of reflux events reaching the proximal esophagus than those with normal motility (P < 0.03), which in contrast to IPF, seemed not to associate with worse pulmonary function. DISCUSSION: Associations between esophageal motility, and lung mechanics and function, and consequently reflux, are very disease-specific.

29 March 2025 in Respiratory Medicine
Verified
Journal Article
Closed access
PBPrasanth Balasubramanian
Prasanth Balasubramanian
ABAlanna Barrios-Ruiz
Alanna Barrios-Ruiz
ALAlejandra Yu Lee-Mateus
Alejandra Yu Lee-Mateus
SVSofia Valdes-Camacho
Sofia Valdes-Camacho
BVBryan F. Vaca-Cartagena
Bryan F. Vaca-Cartagena
DADavid Abia-Trujillo
David Abia-Trujillo

11 January 2023 in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Verified
Journal Article
Open access
PJPatrick W. Johnson
Patrick W. Johnson
KKKatie L Kunze
Katie L Kunze
JSJonathon W. Senefeld
Jonathon W. Senefeld
JSJorge E. Sinclair
Jorge E. Sinclair
SIShahin Isha
Shahin Isha
LSLeigh L. Speicher
Leigh L. Speicher
To test the hypothesis that the Monoclonal Antibody Screening Score performs consistently better in identifying the need for monoclonal antibody infusion throughout each "wave" of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant predominance during the coronavirus disease 2019 (COVID-19) pandemic and that the infusion of contemporary monoclonal antibody treatments is associated with a lower risk of hospitalization. In this retrospective cohort study, we evaluated the efficacy of monoclonal antibody treatment compared with that of no monoclonal antibody treatment in symptomatic adults who tested positive for SARS-CoV-2 regardless of their risk factors for disease progression or vaccination status during different periods of SARS-CoV-2 variant predominance. The primary outcome was hospitalization within 28 days after COVID-19 diagnosis. The study was conducted on patients with a diagnosis of COVID-19 from November 19, 2020, through May 12, 2022. Of the included 118,936 eligible patients, hospitalization within 28 days of COVID-19 diagnosis occurred in 2.52% (456/18,090) of patients who received monoclonal antibody treatment and 6.98% (7,037/100,846) of patients who did not. Treatment with monoclonal antibody therapies was associated with a lower risk of hospitalization when using stratified data analytics, propensity scoring, and regression and machine learning models with and without adjustments for putative confounding variables, such as advanced age and coexisting medical conditions (eg, relative risk, 0.15; 95% CI, 0.14-0.17). Among patients with mild to moderate COVID-19, including those who have been vaccinated, monoclonal antibody treatment was associated with a lower risk of hospital admission during each wave of the COVID-19 pandemic.

24 May 2025 in Chest
Verified
Journal Article
Closed access
JDJuan D. Deleija
Juan D. Deleija
SSSadia Z Shah
Sadia Z Shah
JFJamie Felzer
Jamie Felzer
XTXin Tan
Xin Tan
CGChris Garvey
Chris Garvey
AKAnupam Kumar
Anupam Kumar